ImmuPharma (LON:IMM) Trading Up 27.3% - Here's What Happened

Key Points

• ImmuPharma's stock surged by 27.3% during mid-day trading, reaching a price of GBX 12.60 ($0.17) from a previous close of GBX 9.90 ($0.13).
• Approximately 4.5 million shares were traded, indicating a 46% decline from the average daily volume.
• ImmuPharma reported a negative earnings per share of GBX (0.38) for the last quarter and forecasted a significantly negative EPS of -339 for the current fiscal year.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price rose 27.3% during mid-day trading on Saturday . The company traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). Approximately 4,543,810 shares traded hands during mid-day trading, a decline of 46% from the average daily volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Stock Up 27.3%

The stock has a 50-day simple moving average of GBX 7.92 and a 200-day simple moving average of GBX 4.36. The firm has a market capitalization of £63.34 million, a PE ratio of -1,415.73 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Equities analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.